Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors by Sumanta Kumar Pal, Robert A. Figlin

Get full text

Renal cell carcinoma: An update for the practicing urologist by Sumanta K. Pal, Paulo Bergerot, Robert A. Figlin

Get full text

A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models. by Hao Zhang, Dror Berel, Yanping Wang, Ping Li, Neil A Bhowmick, Robert A Figlin, Hyung L Kim

Get full text

Myeloid clusters are associated with a pro-metastatic environment and poor prognosis in smoking-related early stage non-small cell lung cancer. by Wang Zhang, Sumanta K Pal, Xueli Liu, Chunmei Yang, Sachin Allahabadi, Shaira Bhanji, Robert A Figlin, Hua Yu, Karen L Reckamp

Get full text

Identification of a 4-microRNA signature for clear cell renal cell carcinoma metastasis and prognosis. by Xiwei Wu, Lihong Weng, Xuejun Li, Chao Guo, Sumanta K Pal, Jennifer M Jin, Yuping Li, Rebecca A Nelson, Bing Mu, Susan H Onami, Jeffrey J Wu, Nora H Ruel, Sharon P Wilczynski, Hanlin Gao, Maricela Covarrubias, Robert A Figlin, Lawrence M Weiss, Huiqing Wu

Get full text

The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC) by Brian I. Rini, Dena Battle, Robert A. Figlin, Daniel J. George, Hans Hammers, Tom Hutson, Eric Jonasch, Richard W. Joseph, David F. McDermott, Robert J. Motzer, Sumanta K. Pal, Allan J. Pantuck, David I. Quinn, Virginia Seery, Martin H. Voss, Christopher G. Wood, Laura S. Wood, Michael B. Atkins

Get full text